These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Can we do better in developing new drugs for Alzheimer's disease? Gauthier S; Scheltens P Alzheimers Dement; 2009 Nov; 5(6):489-91. PubMed ID: 19896588 [TBL] [Abstract][Full Text] [Related]
24. Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials. Hung A; Schneider M; Lopez MH; McClellan M J Manag Care Spec Pharm; 2020 Jul; 26(7):888-900. PubMed ID: 32584672 [TBL] [Abstract][Full Text] [Related]
26. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease. Shoaib M; Kamal MA; Rizvi SMD Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531 [TBL] [Abstract][Full Text] [Related]
27. [Preclinical AD and Biomarker; from J-ADNI to AMED Preclinical Study]. Suzuki K Brain Nerve; 2017 Jul; 69(7):691-700. PubMed ID: 28739982 [TBL] [Abstract][Full Text] [Related]
28. Barriers to drug discovery and development for Alzheimer disease. Fillit HM; O'Connell AW; Brown WM; Altstiel LD; Anand R; Collins K; Ferris SH; Khachaturian ZS; Kinoshita J; Van Eldik L; Dewey CF Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S1-8. PubMed ID: 12070355 [TBL] [Abstract][Full Text] [Related]
31. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Cummings JL; Doody R; Clark C Neurology; 2007 Oct; 69(16):1622-34. PubMed ID: 17938373 [TBL] [Abstract][Full Text] [Related]
32. An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy. Ashraf GM; Tabrez S; Jabir NR; Firoz CK; Ahmad S; Hassan I; Alexiou A; Kamal MA Curr Drug Metab; 2015; 16(8):719-27. PubMed ID: 26560324 [TBL] [Abstract][Full Text] [Related]
33. Global measures: utility in defining and measuring treatment response in dementia. Reisberg B Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241 [TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapy of Alzheimer disease. Seow D; Gauthier S Can J Psychiatry; 2007 Oct; 52(10):620-9. PubMed ID: 18020110 [TBL] [Abstract][Full Text] [Related]
35. Slowing the progression of Alzheimer disease: methodologic issues. Leber P Alzheimer Dis Assoc Disord; 1997; 11 Suppl 5():S10-21; discussion S37-9. PubMed ID: 9348423 [TBL] [Abstract][Full Text] [Related]
37. [Alzheimer drugs for mild cognitive impairment]. Fellgiebel A Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184 [TBL] [Abstract][Full Text] [Related]
38. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? Ehret MJ; Chamberlin KW Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885 [TBL] [Abstract][Full Text] [Related]
39. [New diagnostic guidelines for Alzheimer's disease by NIA/AA]. Ihara R Nihon Rinsho; 2016 Mar; 74(3):386-94. PubMed ID: 27025074 [TBL] [Abstract][Full Text] [Related]
40. The pharmacologic treatment of Alzheimer's disease: a guide for the general psychiatrist. Flint AJ; van Reekum R Can J Psychiatry; 1998 Sep; 43(7):689-97. PubMed ID: 9773218 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]